Skip to content
Webe Honey – Lifestyle
Home
Sample Page
Author:
Greywolf Therapeutics
Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types
June 2, 2026
Greywolf Therapeutics appoints Edwin Moses as Chair
April 16, 2026